lung cancer
Conditions
Interventions
Sponsors
Hiroshima University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Selection criterion at enrollment 1)Patients who were diagnosed as lung cancer according to pathology and cytology 2)Patients who will recieve chemotherapy involving cisplatin more than once. 3)Performance status is 0 to 1 4)Gender: no specification 5)Age>20,<75 6)Hospital admission or outpatient department 7)Adequate organ function 8)Agreement to sigh an informed consent
Exclusion criteria
Exclusion criteria: 1)Patients who underwent gastrectomy 2)Patients for whom oral administration was impossible 3)Patients who have another active malignancy 4)Patients with cachexia 5)Patients who does not have an estimated life expectancy of more 3 month 6)Patients who were administered durgs prohibited or KAMPO medicine 2 weeks before entry 7)Drug allergy for Rikkunshito 8)Patients who are pregnant,considering pregnancy or lactaing 9)Patients who are regarded in eligible by the doctor who participates in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Food intake (rate of decreased calorie intake (%)) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)The number of times that patients could not eat a meal at all. 2) VAS of appetite 3) QOL score for emesis (Functional Living index Emesis(FLIE) scale) 4) QOL score (EORTC scale) 5) Grade of CTCAE 6) Plasma ghrelin level(acyl-ghrelin and desacyl-ghrelin) 7) Adverse events 8) Side effects | — |
Countries
Japan
Contacts
Public ContactTomoharu Yoshiya
Hiroshima University Surgical Oncology
Outcome results
None listed